Extract

This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement. Biological therapies, such as lenalidomide and blinatumomab, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing.

Inclusion criteria

• B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma,CD19 Positive,Mediastinal Lymphoma,Recurrent Adult Burkitt Lymphoma,Recurrent Diffuse Large B-Cell Lymphoma,Recurrent Grade 1 Follicular Lymphoma,Recurrent Grade 2 Follicular Lymphoma,Recurrent Grade 3 Follicular Lymphoma,Recurrent Mantle Cell Lymphoma,Recurrent Marginal Zone Lymphoma,Recurrent Non-Hodgkin Lymphoma,Recurrent Small Lymphocytic Lymphoma

Links

• nct
• ictrp